MK-677 Half Life: What the Research Reports

What is the half life of MK-677?

MK-677 half life is best understood as its duration of action: it stays active long enough to be dosed once per day by mouth, though a precise, well-published plasma constant is hard to pin to a verifiable source.

Here is the honest picture. Two human studies dosed MK-677 once daily by mouth and reported a sustained rise in GH and IGF-1: a 1996 dose-ranging study in healthy elderly subjects (Chapman et al., JCEM 1996; doi:10.1210/jcem.81.12.8954023) and a 2-year trial in healthy older adults (Nass et al., Ann Intern Med 2008; doi:10.7326/0003-4819-149-9-200811040-00003). That once-daily schedule is the strongest public evidence that a single dose works for roughly a full day. Detailed human plasma pharmacokinetic values in the openly accessible peer-reviewed literature are limited, and the specific "about 24 hours" figure repeated on vendor pages is not tied to a primary source we could verify. So this page will not attach a hard "X hours" number to a source it cannot stand behind. What is documented is the practical result: one oral dose, once a day, held the hormone response up (Chapman et al., 1996; Nass et al., 2008).

If you only want the takeaway: MK-677 is long-acting, and the sustained GH and IGF-1 response is why the published research used once-daily oral dosing.

Why does MK-677 support once-daily oral dosing?

Because a single oral dose kept GH and IGF-1 raised across roughly a full day in the trials that studied it.

MK-677 is one of the few GH-pathway compounds that works taken by mouth. Most GH secretagogues are injected. In the 1996 dose-ranging study, once-daily oral MK-677 at 25 mg raised the mean 24-hour GH concentration by about 97% and lifted IGF-1 from about 141 to about 265 micrograms per liter over 4 weeks (Chapman et al., 1996). In the later 2-year study, once-daily oral MK-677 at 25 mg produced a roughly 1.8-fold rise in 24-hour mean GH and a 1.5-fold rise in IGF-1 at 12 months, without daily injections (Nass et al., 2008). That combination, oral route plus long duration, is the reason it draws interest as a once-daily option in research settings.

What is the difference between half life and duration of action for MK-677?

Half life is how long it takes blood levels of the compound to fall by half, while duration of action is how long the downstream GH and IGF-1 response lasts, and for MK-677 the second one is what matters for once-daily dosing.

The two often get merged into a single "24-hour" claim, but they are not the same thing. IGF-1 is a slow-moving, integrated marker: it reflects average GH activity over time rather than moment-to-moment pulses. So even after the compound itself starts to clear, IGF-1 can stay raised. That is why a duration-of-effect number tends to look longer than a strict plasma clearance number, and why people round MK-677 to "about a day."

How does MK-677's duration compare to injectable GH secretagogues?

MK-677 is oral and long-acting, sitting closer to long-acting CJC-1295 with DAC than to a short pulse agent like ipamorelin.

The ranges below reflect what published studies report. This is educational, not a prescription or a personal recommendation.

The pattern is the point. A short-acting pulse agent produces a sharper, briefer, selective GH release (Raun et al., 1998). A long-acting design keeps levels up for a week or more per dose (Teichman et al., 2006). MK-677 lands in the sustained camp, delivered orally (Nass et al., 2008).

Does a longer half life mean MK-677 is safer or better?

No. A longer duration of action also means the side effects last, and in a 2-year trial MK-677 raised fasting glucose and lowered insulin sensitivity (Nass et al., 2008).

Sustained signaling cuts both ways. The steady hormone response is what makes once-daily oral dosing possible, but the same steady exposure sustained the metabolic changes seen in the 2-year study: fasting blood glucose rose by about 5 mg/dL and insulin sensitivity by the QUICKI index fell over 12 months (Nass et al., 2008). "Long-acting" describes how the compound behaves, not whether it is right for any one person. Those are separate questions, and the second belongs with a qualified clinician.

What did the human research report for dose and duration?

In the 2-year trial, participants received 25 mg of oral MK-677 once daily, and GH and IGF-1 stayed raised for the duration (Nass et al., 2008).

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

This is research-reported information, not a recommendation. It describes what participants received in one published trial. Any personal dose, schedule, or decision to use MK-677 should be set with a qualified clinician who can weigh the metabolic findings above.